Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) Short Interest Declined By 6.73%

June 27, 2018 - By Heather Owens

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Corporate Logo

Big Money Sentiment decreased to 1.05 in 2018 Q1. It has change of 0.14, from 2017Q4’s 1.19. The ratio worsened due to Tetraphase Pharmaceuticals, Inc. positioning: 15 sold and 23 reduced. 13 funds amassed holdings and 27 increased holdings. Investors holded 29.51 million in 2017Q4 but now own 19.93 million shares or 32.47% less.
Dow De stated it has 0.07% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). California Employees Retirement Sys holds 0% or 220,200 shs. Parametric Portfolio Assoc Limited has invested 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Daiwa Securities Gru holds 0% or 284 shs. Blackrock holds 4.02 million shs. Susquehanna Interest Grp Limited Liability Partnership owns 17,268 shs. Tiaa Cref Ltd Liability Company holds 0% or 162,919 shs. Teton Advisors reported 43,000 shs or 0.01% of all its holdings. New York State Common Retirement Fund invested 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Parallax Volatility Advisers Lp holds 0% of its capital in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) for 1,600 shs. Renaissance Techs Ltd holds 952,185 shs. Jacobs Levy Equity Management Incorporated reported 147,400 shs. Panagora Asset holds 558,891 shs or 0.01% of its capital. New York-based Jane Street Gru Inc Lc has invested 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Citigroup stated it has 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH).

Tetraphase Pharmaceuticals, Inc. had 2 selling transactions and 0 insider buys since January 9, 2018. This’s net activity of $98,932.

Change of 6.73% for Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH)’s short interest was reported. In June was announced TTPH’s total 3.18M short interest by FINRA. The down change of 6.73% from 3.41 million shares was reported. With Average volume 624,000, TTPH’s former position will take 5 days to recover. Tetraphase Pharmaceuticals Inc float short is 6.56%.

TTPH touched $3.77 during the last trading session after $0.11 change.Tetraphase Pharmaceuticals, Inc. has 799,253 shares volume, 12.83% up from normal. TTPH is downtrending and has moved 48.55% since June 27, 2017. TTPH underperformed by 61.12% the S&P500.

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections.The firm is valued at $194.65 million. The Company’s lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.Last it reported negative earnings. The firm has completed a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and initiated a Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Ratings Coverage

Total analysts of 6 have positions in Tetraphase Pharmaceutical (NASDAQ:TTPH) as follows: 5 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 83%. The firm has $11 highest while $3 is the lowest PT. The average target $7.20 is 90.98% above the last ($3.77) price. Since February 12, 2018 according to StockzIntelligence Inc Tetraphase Pharmaceutical has 12 analyst reports. On Wednesday, February 21 the company was maintained by FBR Capital. The company rating was maintained by SunTrust on Wednesday, February 14. On Tuesday, February 27 the stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) earned “Buy” rating by FBR Capital. In Wednesday, February 14 report BMO Capital Markets downgraded the stock to “Market Perform” rating. On Monday, February 12 FBR Capital initiated the shares of TTPH in report with “Buy” rating. On Thursday, March 8 the stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) earned “Market Perform” rating by BMO Capital Markets. On Monday, June 11 the stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has “Buy” rating given by FBR Capital. On Wednesday, March 7 FBR Capital maintained Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) with “Buy” rating. On Monday, June 4 FBR Capital maintained Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) with “Buy” rating. On Thursday, March 29 the rating was upgraded by Gabelli to “Buy”.

A couple more Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) news were posted by: Seekingalpha.com which released on June 13, 2018 “Your Daily Pharma Scoop: Tetraphase Positive Data, MediWound In Phase 3, Allergan Moves Up”, also Streetinsider.com on June 11, 2018 posted “Tetraphase Pharma (TTPH) Reports Positive Data from a Pooled Analysis of IGNITE1 and IGNITE4 Phase 3 Trials”, the next Globenewswire.com is “Detailed Research: Economic Perspectives on Tetraphase Pharmaceuticals, Tech Data, Southern National Bancorp of …” on June 21, 2018. Seekingalpha.com has article titled “Tetraphase Pharma’s eravacycline shows positive effect in late-stage studies; shares up 6% premarket”.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.